Kristie L. Kahl

At the 2019 Genitourinary Cancers Symposium, Arjun V. Balar discussed the past, present and future of immunotherapy for the treatment of bladder cancer.

At CURE’s patient-focused meeting at the 36th Annual Miami Breast Cancer Conference, Shannon Pulaski and Ellen Matloff discussed the importance of genetic counseling and learning more about one’s family health history.

The Food and Drug Administration approved the VENTANA PD-L1 (SP142) Assay as the first companion diagnostic to aid in identifying patients with triple-negative breast cancer who are eligible for treatment with Tecentriq (atezolizumab) plus chemotherapy.

Time-limited treatment could be the new wave of research in the treatment of chronic lymphocytic leukemia (CLL), according to Nicole Lamanna, M.D.

The oral blood thinner Xarelto (rivaroxaban) significantly reduced blood clots for high-risk patients with cancer being treated in the outpatient setting, according to results from the CASSINI trial.

In this week’s episode, we spoke with a patient advocate and survivor of renal cell carcinoma to help raise awareness during Kidney Cancer Awareness month.

Sameek Roychowdhury, M.D., Ph.D., discusses the importance of molecular testing to determine treatment options for cholangiocarcinoma.

Frontline use of Bavencio (avelumab) plus Inlyta (axitinib) significantly improved progression-free survival compared with the standard of care in patients with advanced renal cell carcinoma.

The one-day agenda hosts faculty and panels discussing breast cancer treatments and their side effects, genetics, survivorship, and more.

In this week’s episode, we spoke with actor Scott Foley, who opened up about his experience as a caregiver to his mother after her ovarian cancer diagnosis and why he joined the Not on My Watch movement to help educate others.

A liquid biopsy test detected all of the guideline-recommended biomarkers in newly diagnosed patients with metastatic non-small cell lung cancer at a similar rate but faster than tissue genotyping.

Outcomes associated with subcutaneous injections of Darzalex (daratumumab) appeared similar to IV administration in patients with relapsed or refractory myeloma, according to the phase 3 COLUMBA trial.

After patients with non–muscle invasive bladder cancer fail to respond to treatment with BCG immunotherapy, Keytruda (pembrolizumab) may induce responses in these high-risk patients.

In this week’s episode of the CURE Talks Cancer podcast, we spoke with a childhood cancer survivor about her journey with stage 4 neuroblastoma, and also about taking part in the St. Jude LIFE research program.

The Food and Drug Administration granted a priority review to Tibsovo (ivosidenib) for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) with an IDH1 mutation who are not eligible for standard therapy.

The Food and Drug Administration granted a priority review to Keytruda (pembrolizumab) for the third-line treatment of patients with advanced small cell lung cancer (SCLC).

Vofatamab (B-701) may be safe and effective for patients with locally advanced or metastatic bladder cancer with an FGFR3 mutation who have relapsed after, or are refractory to, at least one prior line of chemotherapy, according to preliminary findings.

The Food and Drug Administration granted a priority review to polatuzumab vedotin in combination with bendamustine plus Rituxan (rituximab) for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

The Food and Drug Administration (FDA) granted a priority review to entrectinib for the treatment of adult and pediatric patients with neurotrophic tropomyosin receptor kinase (NTRK) fusion-positive, locally advanced or metastatic solid tumors and for metastatic, ROS1-positive non-small cell lung cancer.

The Food and Drug Administration granted a priority review to Keytruda (pembrolizumab) in combination with Inlyta (axitinib) as a frontline treatment for advanced renal cell carcinoma.

This week, we spoke with FORCE to dispel some of the misconceptions associated with at-home genetic testing for hereditary cancer risk.

An integrative model helped to determine which patients with bladder cancer may benefit from checkpoint inhibitor therapy.

CURE® spoke with CEO Linda Tantawi about addressing the needs of underserved communities and how education is key in helping women in the Greater New York City area.

The Food and Drug Administration granted a priority review to Bavencio (avelumab) in combination with Inlyta (axitinib) to treat patients with advanced renal cell carcinoma (RCC).

Imbruvica (ibrutinib) may be superior to standard of care in elderly patients with untreated chronic lymphocytic leukemia (CLL), according to phase 3 findings published in the New England Journal of Medicine.

The Food and Drug Administration granted a priority review to the supplemental biologics license application for Keytruda (pembrolizumab) for the first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).

Check out this week’s quick overview of what is making headlines in the cancer space.

This week, we spoke with two faculty members from the patient-focused meeting at the upcoming Miami Breast Cancer Conference.

Researchers are evaluating the use of folate receptors to treat platinum-resistant ovarian cancer.

Meeting combined exercise guidelines improved quality of life in kidney cancer survivors; however, few individuals reported that they actually follow such guidelines.